Brussels South Charleroi BioPark announces strong Q1 2020 performance

April 27th 2020


Transaction flow reaches historical value above €500M involving high profile international partners

Brussels South Charleroi BioPark (BSCB), announces a strong performance at Q1 2020 and confirms growth ambitions.

Despite the Coronavirus crisis, Brussels South Charleroi BioPark, which gathers 70+ biotech and biopharma players, booked a historically strong performance in the first quarter of 2020. Created 20 years ago by the University of Brussels (Université Libre de Bruxelles (ULB)), the BioPark also confirmed its growth ambitions underscoring its leading role in the Life Sciences sector.

Several BioPark players and their hospital network are also actively contributing to the COVID-19 fight and are making their expertise, platforms and infrastructure available to enhance collaborative efforts. Please discover the press release here.